Read EHF White Paper and Brochure in 18 languages. The Pre-ICO will be launched on May 10, 2018. The Smart Contract code is available on GitHub. The White List is live!
Close
eHealth First ICO

An IT-platform for Personalized Health and Longevity Management
based on Blockchain, Artificial Intelligence,
Machine Learning and Natural Language Processing

For healthy people, patients and health professionals
Comprehensive IT Platform + 2 related web / mobile apps
23 Team Members from 9 countries
Watch the Video
Private Placement is almost completed
December 1, 2017 - April 9, 2018
up to 1 000 000
Number of tokens
NO DAILY LIMIT
45-70%
BONUS
Flexible
Conditions and price for a block of tokens
2 ETH or 0.2 BTC
Minimal investment size
Pre-ICO is coming soon
White List is live!
May 10, 2018 - June 10, 2018
up to 1 500 000
Number of tokens
NO DAILY LIMIT
up to 40%
BONUS
0.006 ETH
Price at launch
+0.25%
Daily price increment
We are on Media
" A group of healthcare professionals and AI experts asked themselves a fascinating question: Why not take medical data, which we know can be easily gathered and secured on a distributed ledger, and process it using AI and machine learning algorithms?
They realized, through the effective use of AI, a mass quantity of up-to-date data from biomedical research can be summarized and personalized in an efficient and time-effective manner. In essence, commonalities can be found between the medical data of the individual and the research in order to establish personalized diagnoses and medical recommendations.
Now, this group of visionaries has come together as a new company called eHealth First. "
" In today's digitizing world, technology is progressing fast, and our lives are being improved on a daily basis as a result. What's more, bitcoin and other cryptocurrency prices are soaring, and our economy is being decentralized - and made more transparent - as a result.
Robotics, AI algorithms, and neural networks are increasingly being used to automate just about everything. Data can now be gathered and processed with ease, taking the information age just one step further since the rise of the internet...
Clearly, these ... key trends in technological advancement can be used to make healthcare more accessible on the national - and even on the international - level. One new startup - eHealth First - is bringing all three of them together to do just that. "
" eHealth First wants to revolutionize global healthcare, not just health care for a rich elite. And while the majority of the world might not have a tablet or laptop computer, the great majority do have smartphones. Using smartphones to access health records and information not only allows for unprecedented ease of access (courtesy of the blockchain) in both the developed and developing world.
The world is living longer and longer and that means that health records are getting longer, too. And with them, the bills.
The world is currently experiencing an explosion of the population of the aged and aging, and a whole slew of problems are coming to light that has never before been experienced. Modern medicine has made commonplace what was once a rarity: old age.
eHealth First's system is uniquely suited to tackle this problem as the management of healthcare records is uniquely crucial with aged folks. "
" However, even bigger news for the cryptocurrency community has been the development of the utility token, which serves as the means of exchange within and beyond the decentralized applications. They are a great tool for startups with cool ideas to raise funding without the need to rely on some centralized investment fund.
eHealth First (EHF) is one of these startups. The project's team, uniting healthcare professionals, physicians, and computer scientists, aims to change the world for the better with a new platform that will help people manage their health.
EHF is the first health platform combining the most advanced machine learning, artificial intelligence, data processing, and blockchain technologies. The platform consists of two related software apps that can quickly reference necessary medical information from a single database of medical literature. "
" You have probably read about a lot of cryptocurrency projects and ICOs. As a whole, this new way of getting funding - initial coin offerings - is changing the way companies are formed and start-ups grow into successful businesses.
Often, ICO projects have really great teams behind them. Some projects, however, have teams made up only of true experts. eHealth First is one of these projects.
... Medical recommendations will be made with the help of AI algorithms that process vast databases of medical literature. Users will have the option to analyse specific body systems and additional diagnostic models, as well as seek laboratory tests and medical consultations through the app. "
" Now, these medical and computing experts are ready to announce that they have begun work on a platform – eHealth First – that will allow users to do just that. EHF consists of two applications. The first is a user-friendly mobile and web application that allows users to get diagnoses and recommendations that improve medical conditions and increase lifespans. The second is an open platform for medical professionals, that allows specialists to access medical research data in order to build other platforms specializing in a wide array of medical conditions and diagnoses ...
Imagine you're on vacation in Thailand and your chronic skin condition acts up. A doctor in Thailand will be able to access your medical records from back home – securely – and see your home doctor's diagnosis, and the treatment that has worked for you in the past. "
" Given the number of people who are using the internet nowadays, a huge amount of data is being created every single day, minute, and second. In fact, each minute of 2017, 156 million emails and 16 million text messages were sent, 46,200 images were uploaded to instagram, and 452,000 tweets were tweeted. That's a lot of data.
And this data is useful. In the most basic sense, it helps social media and other platforms to match you with information, entertainment, businesses, and products that would interest you the most. Now, finding things to read, watch, buy, and do, is getting easier than ever.
However, it's really about time for big data to do something that will truly improve people's lives. It's time for big data to revolutionize healthcare.
And eHealth First is at the forefront of this movement. "
" Whether your goal is to track a chronic condition or to just simply improve your health overall, eHealth First may just be the app for you.
The user experience on the app has three key phases – analysis, diagnosis, and recommendation or further analysis. Data on the app is stored securely – mostly utilizing blockchain technology (distributed ledgers) to encrypt and distribute personal data in a decentralized manner – meaning nobody but yourself can access it.
During the analysis phase, the user undergoes initial screening. This preliminary analysis appears to the user as a simple questionnaire. Behind the scenes, however, the questions are based on the principles of evidence-based medicine.
Based on this questionnaire, a rough estimation of the user's health is found, considering the biological age, placement on the frailty index, and status of various body systems. At this point, a rough "diagnosis" will have been established. AI algorithms will then use this estimation to determine which further tests the user might need. "


" IT-платформа EHF Personal Health: веб-портал и мобильное приложение с интегрированной экспертной системой на основе технологий блокчейна, машинного обучения, анализа естественного языка, нейронных сетей, «больших данных», клинической эпидемиологии, доказательной медицины и телемедицины, функционирующее в форматах B2C и B2B.
Система направлена на непрерывный мониторинг, первичную предварительную диагностику (скрининг) и формирование оптимального алгоритма лечения и профилактики наиболее распространённых заболеваний и состояний.
В качестве основы для выработки индивидуальных рекомендаций используются результаты миллионов опубликованных биомедицинских исследований и персональные данные пользователя – параметры, характеризующие здоровье.
Владельцы EHF-токенов смогут: получать доход от инвестиций в случае роста цены токенов и обменять токены на другие криптовалюты (BTC, BCC, ETH и т.д.) или на «фиатные» деньги (USD, EUR, JPU, CNY и т.д.); использовать токены как платёжное средство и дополнительно получать 30-50% скидку на любые услуги в рамках проекта EHF (Healthy Life, MedSearch) и у партнёров проекта; использовать токены для участия в разработке проекта путём голосования. Предусмотрены и другие возможности для владельцев токенов. "
" eHealth First, eine neue Plattform für das Gesundheitsmanagement, zielt darauf ab, die Gesundheitsergebnisse und die Langlebigkeit zu verbessern, indem diese medizinische Literatur sowie personalisierte Diagnosetechniken genutzt werden. Sie planen, dies im mobilen Format zu tun und die neuesten KI-, Datenverarbeitungs- und Blockchain-Technologien zu nutzen, um dieses Ziel zu erreichen.
Ob Ihr Ziel ist es, eine chronische Erkrankung zu verfolgen oder einfach nur Ihre Gesundheit insgesamt zu verbessern, kann eHealth First nur die App für Sie sein. Die Nutzererfahrung in der App umfasst drei Schlüsselphasen – Analyse, Diagnose und Empfehlung oder weitere Analyse. Daten auf der App werden sicher gespeichert – meist unter Verwendung der Blockchain-Technologie (verteilte Bücher), um personenbezogene Daten dezentral zu verschlüsseln und zu verteilen – dh niemand außer Ihnen selbst kann darauf zugreifen.
Das eHealth First Project weist hohe finanzielle Indikatoren auf und nennt (für das konservative Szenario) NPV (12%, 10 Jahre) = 600 Millionen USD, IRR> 50%, EV (Y2023) = 1,4 Milliarden. US DOLLAR.
EHF wird mit einem Blockchain-emergierten (ERC20-Standard) Utility-Token arbeiten. Benutzer können mithilfe dieses Tokens Dienste auf der Plattform erwerben. "

" A eHealth First é uma plataforma de TI para suportar tomada de decisão no campo da gestão de saúde, longevidade, diagnóstico, prevenção e tratamento de doenças comuns para usuários não especializados, especialistas médicos e pesquisadores.
As pessoas usarão o aplicativo e o website para: Armazenar dados clínicos no blockchain; Compartilhar seu histórico de informações com profissionais; Controlar e monitorar seu histórico; Ter acesso à telemedicina on demand; Encontrar hospitais e centros de saúde próximos. Profissionais da saúde poderão usar para: Obter informações precisas e atualizadas sobre o histórico do paciente; Manter contato com um paciente; Fornecer telemedicina; Verificar recomendações de clinicas e hospitais.
O pré-ICO tem data de início no dia 18 de Março de 2018 e vai até 18 de abril. O ICO está programado para começar em junho. Haverá um desconto de até 40% para quem comprar no Pré-ICO. "
" Platforma bude obsahovat řadu konkrétních a ověřených dotazníků s nejvyšší možnou mírou účinnosti v diagnostice. Platforma zahrnuje dva související softwarové produkty.
První z nich je mobilní aplikace pro osobní zdravotní péči (EHF Personal Health)s integrovaným systémem, který poskytuje poradenské služby pro uživatele, zdravotnické pracovníky a odborníky. Systém zahrnuje sběr a ukládání osobních údajů uživatelů a bude odpovídat normám právních předpisů v oblasti ochrany osobních údajů.
Druhý je IT platforma pro zdravotnické pracovníky (EHF Biomed), která bude mít vlastnosti databáze a analytického systému v oblasti biomedicíny a příbuzných oborů. Klíčovým prvkem aplikace bude neustále aktualizovaná databáze o procesech stárnutí a biomedicínských možnostech zpomalení tohoto procesu.
Na platformě eHealth First se pro platby použije token EHF. Pro platby v tokenech budou mít členové ekosystému slevy. Současně budou tokeny poskytovat držitelům EHF hlasovací práva při výběru nového výzkumu a podobného hlasování. Tokeny budou rovněž obchodovány na burzách po ukončení ICO. "


Private Placement
Private Placement is the most beneficial for an investor stage of ICO and provides maximal bonus (50-70% discount to the ICO, Round 1, price) depends on:
- the investment size;
- day of purchase of EHF tokens (December 1, 2017 - February 17, 2018, the sooner the more profitable).
The minimal investment size is 2 ETH.
The smart contract isn't active for this Stage and all the transactions are handled manually.
Your Name
Optional
Your Email *
Your Ethereum account A address, using for the payment in ETH *
Your Ethereum account B address to get EHF tokens *
The ETH Accounts A and B could be the same
How many ETH are you investing at the Private Placement stage? *
Please note, minimal value is 2 ETH. The Bonus Amount depends on the investment size. If you plan to invest less than 10 ETH, please wait for the Pre-ICO Stage.
Leave your comments
You'll get the EHF Ethereum account address (to make the payment in ETH) just after successful submission of this form.
In case of questions, please write at support@ehfirst.io or to the Official Telegram Group.
Thank you!
Private Placement
Private Placement is the most beneficial for an investor stage of ICO and provides maximal bonus (50-70% discount to the ICO, Round 1, price) depends on:
- the investment size;
- day of purchase of EHF tokens (December 1, 2017 - February 17, 2018, the sooner the more profitable).
The minimal investment size is 0.2 BTC.
The smart contract isn't active for this Stage and all the transactions are handled manually.
Your Name
Optional
Your Email *
Your Bitcoin Account A address, using for the payment in BTC *
Your Ethereum Account B address to get EHF tokens *
How many BTC are you investing at the Private Placement stage? *
Please note, minimal value is 0.2 BTC. The Bonus Amount depends on the investment size. If you plan to invest less than 0.5 ETH, please wait for the Pre-ICO Stage.
Leave your comments
You'll get the EHF Bitcoin account address (to make the payment in BTC) just after successful submission of this form.
In case of questions, please write at support@ehfirst.io or to the Official Telegram Group.
Thank you!
Private Placement
Private Placement is the most beneficial for an investor stage of ICO and provides maximal bonus (50-70% discount to the ICO, Round 1, price) depends on:
- the investment size;
- day of purchase of EHF tokens (December 1, 2017 - February 17, 2018, the sooner the more profitable).
The minimal investment size is is 2500 USD / 2000 EUR.
The smart contract isn't active for this Stage and all the transactions are handled manually.
Your Name
Optional
Your Email *
Your Phone number *
Your Ethereum Account B address to get EHF tokens *
What fiat currency would you like to pay with? *
How many USD or EUR are you investing at the Private Placement stage? *
Please note, minimal value is 2500 USD / 2000 EUR. The Bonus Amount depends on the investment size. If you plan to invest less, please wait for the Pre-ICO Stage.
+
Leave your comments
In case of questions, please write at support@ehfirst.io or to the Official Telegram Group.
Thank you!
The idea and vision
Everyone wants to live an active and healthy life and to live as long as possible. The developments in science and new technologies inspire confidence in imminent solutions to the problems of radical prolongation of life, and the prevention and treatment of cancer and cardiovascular diseases. Cell products and gene therapies are already here. They are the present for biomedical science, but still the future for health care.

In developed countries with universal social security coverage, everyone has access to qualified medical care, preventive programs and balanced nutrition. This is not true for developing countries and developed countries with a market health system. 90% of the world's population lives in such "non-ideal" conditions.
But do the best healthcare systems have no problems?

People turn to doctors. They seek help for a check-up, for advice concerning disease treatment or the prevention of the complications, to discuss their future health perspectives. Medical help should be accessible, timely, effective and safe.
In reality, people face many of the following obstacles:
Information asymmetry
Doctors and patients have different qualifications in matters of health. Patients cannot effectively evaluate and choose a product or service, but must pay for them directly or indirectly. For them the "seller" diagnoses the illness and prescribes treatment, or recommends prevention.
Access to medical records
Patients have limited access to their medical records and often cannot see or correct them. They get instructions on what will be best for them, but do not control important personal information.
Continuity in medical records
In many countries, doctors cannot obtain the medical records of their patients from other hospitals and clinics. Sometimes the continuity of medical information affects the outcomes of treatment.
Length of medical consultations
Attendance time is limited. Patients meet with their doctor for a 10-minute consultation. During this time doctor has to make medical records, make appointments, examine the patient, discusses with them recommendations and possible alternatives, and perhaps reassure patients. It's difficult to have time to do all this in the few allotted minutes, and most of the time doctors are writing or typing, and patients are waiting.
Queues / Waiting time
Getting an appointment with a doctor can take weeks or even months. The same situation occurs with many diagnostic tests. As a result, a person spends months waiting and during this time does not receive real help. This is not a simple inconvenience. The life quality and expectancy of a person depends on the timeliness of medical care.
Cost
The patient cannot or does not want to wait for "free" medical care or the necessary examinations are not covered by insurance. They have to pay for medical services themselves. In the US, for example, paying bills for treatment is the reason for more than half of all household bankruptcies.
Health professionals' knowledge and skills
If patients are diagnosed with a serious illness, they "blindly" follow the doctor's recommendations and do not have a realistic opportunity to check if there is a more effective way. Patients count on the knowledge, skills and expertise of their doctor; on the doctor's experience and ability to make the best decisions about the latest medical science. But the doctors themselves are in a difficult situation, choosing how to "manage their patients" on the basis of their own qualifications and experience, and, perhaps, the views and opinions of colleagues. A doctor cannot study the hundreds of thousands of new annual publications in their field, even if they limit themselves to secondary sources: Cochrane reviews, meta-analyzes or randomized controlled clinical trials of treatment and prevention methods. Do all the doctors really want to constantly learn, maintain a high professional level and help the patient in the most effective way?
Generalized vs. personalized practices
Patients can receive three types of medical prescriptions. The first ones do not have sufficient evidence of efficacy and safety, and are based on one's own experience, beliefs and the doctor's views. In this case, the patient on one occasion receives various recommendations from several doctors. The second ones are proven to be effective and based on the results of high-quality research. This practice is known as "evidence-based medicine". Preferred practices change and are refined as new information becomes available. The third ones are based on the results of high-quality research, but take particular account of the individual characteristics of the patient. This is "personalized medicine". The first ones are most common. More useful but less often encountered, sometimes fatefully, are the second or third types.
A patient has to wait for weeks for medical assistance, pay for it, being unsure about the qualifications of the doctor and their access to medical records. Can this be changed and when?

Yes, and there are seven reasons to foresee the changes:
Show more
The total number of mobile phone users in the world by 2018 is forecasted to exceed 2.5 billion and more than half of all mobile phones will be smartphones that have access to the internet and social networks.
People already receive medical data from wearable gadgets: measuring the heart rate and blood pressure, recording electrocardiograms and performing ultrasounds, evaluating body temperature, glucose levels and blood saturation. There are mobile systems for electroencephalography, spirometry, measuring intraocular pressure and analyzing emotional states.
The synergy of clinical medicine, health science and big data management tools will allow people to maintain health, live longer and better, delay aging. to cure and prevent most of diseases. Millions of useful articles and books are stored electronically. All it takes now is broad high quality access to personalized information; information that answers your questions about health, nutrition, lifestyle, proper medication, preventive intake of dietary supplements, physical activity, vaccination, treatment of diseases, improving life with chronic diseases and more.
This is impossible without the modern technologies of Artificial Intelligence (A.I.), Machine Learning (M.L.), Natural Language Processing (NLP), as no patient or medical professional can successfully manage huge amount of medical information including medical research. Artificial Intelligence (A.I.) is used in the management of "smart cities", the financial sector, production, agriculture, energy. The health sector is no exception. Over the next 10 years, a qualitative leap is expected in the development of the information technologies, and their successful application at the different levels of government, insurance companies, hospitals, doctors and individual patients.
People understand more and more about health issues, they are interested in avoiding illness or finding treatment for themselves and their beloved ones. Faced with the disease, some of them look for scientific and popular publications on the internet, and try to apply the information they find. Individuals can now become centers for collecting and analyzing health information for themselves and their families. They can make decisions about choosing a doctor, a consultant, the method of diagnosis and treatment, the timing of the beginning and completion of therapy. They can manage their health and their lives.
Telemedicine can, in theory, connect patients and doctors, clients and the health care consultants through a worldwide network, quickly, without queuing, regardless the distance. But if any non-urgent health issue is to be solved by online reception, the next issue is a sufficient number of highly qualified doctors and consultants. Doctors fail all the time even in the best healthcare system to provide the most update and most effective treatment options, as they do not have time to follow rapidly growing medical research. The delays in accommodating medical research data into clinical practice can take decades, and it is critical in many conditions like for cancer patients. Medical research knowledge is significantly underutilized, which means that patients are deprived of their changes to live longer and healthier. There many evidence-based preventive interventions capable to delay pathological processes of aging and prolong healthier lifespan, but they are not getting prescribed to the patients due to inertia in healthcare systems. People often face issues they are uncomfortable to bring to a doctor, like emotional problems, weight loss and maintenance, psychoactive substance use or questions about sex lives. While consulting medical professionals is important in many of such cases, access to the most up-to-date scientific information is a lot better than unqualified advice one can find on the internet.
Blockchain technology can significantly simplify and secure the work with the health data. Using smartphones and computers, people will be able to effectively manage their health: record personal medical data, take tests and fill out forms and applications, choose doctors, get their conclusions and appointments, ask questions, consult, exchange information, voluntarily provide access to the information to one or another specialist and establish, pay for or evaluate services with crypto-currencies. And all this can be done safely, anonymously, and efficiently.
All of us constantly face the problem of timely access to personalized (i.e., reflecting our own bodies and circumstances and the information we need) information on how to maintain, strengthen our health, how to identify a disease and recover from it, and to do this most effectively and cheaper. Ultimately, the question we all live with is how to live longer and better.

The eHealth First project will allow everyone to get the most up-to-date, relevant and personalized information about their health on the basis of an analysis of individual data, and an extensive library of world medical research literature and considerations of the features of the local health systems.

Screening algorithms, individualized diagnoses of the most common diseases and personalized treatment and prevention plans are just a part of what this IT platform will provide to each user.

And for the health professionals, an additional, publicly available solution for automatic analysis of medical publications will be created.

The right and in-time information is the key to health and longevity.

The eHealth First is an IT-platform to support decision-making in the field of health management, longevity, diagnostics, the prevention and treatment of common diseases for non-specialist users, medical specialists and researchers based on blockchain technology, machine learning, natural language analysis, neural networks, big data, clinical epidemiology, evidence-based medicine and telemedicine
The concept
The project is developing and implementing an innovative IT platform for screening and optimal algorithms for maintaining health and diagnosing, treating and preventing various diseases and conditions. A project which is unique.

The platform will include a number of the most sensitive and specific, validated questionnaires with highest possible currently diagnostic effectiveness.

A range of the most sensitive diagnostic methods and the most effective medical interventions (taking into account the need to clarify the diagnosis and prescriptions of the attending physician), as well as most evidence-based lifestyle recommendations will be available on the basis of an innovative open medical knowledge platform in the field of aging and robust longevity. The open platform is being developed using A.I., such as Natural Language Processing methods for the ever-growing body of publications in medical science, machine learning, and neural networks. As a result, the IT platform will reduce the obsolescence of medical knowledge.

The open and free part of the platform will be an ontological network replenished using natural language and neural network processing methods semi-automatically (with expert pre-moderation) with the participation of both project staff and authorized qualified volunteers. The inference and visualization of search queries in a user-friendly intuitive interface based on the ontology project team has already created will greatly facilitate the search for scientific information, and the synthesis and acquisition of new scientific knowledge. This will be one of the first open systems for the deep processing of scientific medical texts and the first such system in the field of aging and longevity research in the world.
The Personal Health Management Application (EHF Personal Health) is a web portal and mobile application with an integrated expert system that provides advisory services in a B2C format for non-specialist users in the field of health, medical professionals, and potentially for other categories of users including experts and employers. The system involves the collection and storage of users' personal data and will comply with the norms of the legislation in the field of personal data protection. It assumes mixed storage of data: centralized and decentralized in the blockchain.

After registration, the user will be asked to undergo preliminary diagnostics screening. This structured questionnaire, compiled on the basis of the principles of evidence-based medicine, consists of questions that identify the basic indicators of health, collect information for categorizing this user within the system, collect estimates of biological age, a frailty index, and also give primary assessments of various body systems. For the preliminary diagnosis, the user does not need to undergo a survey using any laboratory-based methods. The user gives information about the results of previous medical tests and the questionnaire does not require any medical education.

After passing the preliminary diagnostics, the system, using the algorithm developed in the course of the project, will formulate a list of the main recommendations for this user, and also offer additional diagnostics, including the use of specialized validated questionnaires, laboratory tests and medical consultations.

For each specialized diagnostic module, a separate algorithm will be developed that allows the user to clarify the danger of certain pathological conditions or diseases, and to give specific recommendations, including additional biochemical and other analyzes. Access to these modules is planned to be fee based. If the user has started working with the module but does not have the necessary tests to perform diagnostics within this module, they can return to this module later, after the necessary tests have been completed. The system saves the user information for each diagnostic module, and the user can continue to work with the system at any convenient time.

Within the framework of a personalized module, the user is provided with results in a user-friendly form, including assessments of the risk of various types of diseases, recommendations for lifestyle changes, educational information, including advice on the use of medication, scientifically based nutraceuticals and medical devices.

The algorithms of the system are to be constantly improved, updating them based on updated of the second module of the platform. Users will be able to get tested again in accessible modules and get the most up-to-date recommendations.

The application to support health decision-making, personal strategies for the diagnosis, prevention and treatment of diseases for non-specialist healthcare users and health professionals will include:
Show more
an expert system for the primary diagnosis of the most common diseases and conditions on the basis of automated algorithms obtained on the basis of the principles of evidence-based medicine. Based on the tests, recommendations will be generated for laboratory tests and visits to medical specialists to clarify the preliminary diagnosis;
the most up-to-date information on the diagnosis, prevention and treatment of diseases, therapeutic windows, contraindications, drug interactions, semi-automatically updated following new clinical guidelines, systematic reviews and meta-analyzes will be developed using natural language processing (NLP) methods;
indices of the biological age of a person;
a frailty index;
a general module for the primary prevention of age-related diseases;
modules for people with chronic diseases (including those with metabolic syndromes, hypertension, ischemic heart disease, type 2 diabetes, etc.);
special modules for patients with cancer, aimed at improving the quality of their lives.
The open IT platform for health professionals (EHF Biomed) will have the functions of a database and analytical system in the field of biomedicine and related specialties. A key element of the application will be the constantly updated knowledge base on pathological aging processes and bio-medical anti-aging interventions. This knowledge base will be updated semi-automatically with the processing of an array of literature (including the Pubmed / MEDLINE system) using natural language processing, machine learning and neural networks. This knowledge base, presented in the form of a scalable information system, will provide tools for searching and analyzing the most relevant scientific information on any biomedical issues in the field of longevity.

The application provides flexible possibilities for searching information, including using the resulting natural language processing graphs of the relationship between certain terms and text elements.

With the help of natural language processing, machine learning and neural networks in the medical databases, a search will be conducted for a series of keywords related to pathological aging processes, associated signal molecules, potential and approved diagnostic methods and medical interventions. An intuitive, user-friendly structure of the summary of scientific information will significantly reduce the time and improve the accuracy of scientific research.

It will have the most modern meta-analyses and systematic reviews of clinical trials (including Cochrane studies), studies of diagnostic methods, prevention and treatment of pathological aging processes and age-related diseases (indicating the level of evidence obtained on the recognized international scale), and at any given moment will provide access to the most relevant medical knowledge in the framework of biogerontology and age-related diseases.

Users will be able to create individual collections of materials, and subscribe to the appearance of new materials according to the formulated search criteria. Subscribers will receive regular lists of materials of interest through email and messengers.

At the initial stage, the application provides an expert moderator, who will select the most suitable data, and standardize the presentation of these data to users.

The technical feature of the second application is a search index, which allow to quickly find any necessary information in a large database.

The system with integrate with blockchain technology, including the development of a universal format for recording aggregated data from biomedical research.
Use cases
Healthy people and patients
will use the EHF Apps and web-site:
  • to write down, collect and store in blockchain and centralized repositories encrypted complete personal health-related information, including clinical data;
  • to share at will complete personal health-related information, including clinical data, with stakeholders (physicians, health specialists, nutritiologists, psychologists, relatives etc.);
  • to control, monitor and evaluate health status;
  • to get most relevant resultant personalized health-related information and EBM-based recommendations on demand at any time (prevention, screening, diagnosis and treatment of diseases, food, life-style, active longevity etc.);
  • to get "a second opinion" about health condition and health professional's recommendations;
  • to plan and get telemedicine consultations on demand;
  • to find optimal local hospitals, outpatient clinics and health specialists in order to solve a personal health-related issue.
Healthcare providers (physicians, other health professionals, hospitals, outpatient clinics, psychologists, nutritiologists etc.)
will use the EHF Apps and web-site:
  • to get relevant, accurate and up-to-date information about health status of a patient / customer, without wasting time on re-collection of anamnesis at each first consultation;
  • to check clinical recommendations using in-build e-manuals (locally approved drug labels, test methods, validated questionnaires etc.);
  • to recommend to a patient / client use in-build electronic questionnaires and their results in clinical practice;
  • to send medical appointments to a patient via Members Area;
  • to input, store and share with EHF Apps users the information about professional area, education, skills, experience, achievements and contact details;
  • to plan and provide telemedicine consultations on demand;
  • to organize at patient's will online medical consiliums, inviting other health professionals and healthcare providers.
EHF Project Partners – Software Developers
will use the EHF Apps and web-site:
  • to develop, publish, distribute and sell their own health-related applications through EHF Marketplace.
Researchers, public institutions
will use the EHF Apps and web-site:
  • to plan and carry out population studies (observational and clinical ones) on EHF Platform (impersonal data of users, who granted appropriate permission could be used for the study purposes only);
  • to get statistical information about public health and healthcare (impersonal data of users who granted appropriate permission could be used for these purposes only);
  • to search and classify evidence-based biomedical information of their interest.
Industry researchers and commercial companies
will use the EHF Apps and web-site:
  • to plan and carry out population studies (observational and clinical ones) and Patient Support Programs (PSP) on EHF Platform (impersonal data of users who granted appropriate permission could be used for the study purposes only);
  • to inform users about their services and products;
  • to develop, publish, distribute and sell their own health-related applications (modules) through EHF Marketplace, including ones for support their hardware products (test systems, therapeutic equipment, wearables etc.);
  • to search and classify evidence-based biomedical information of their interest.
Key Areas and Technologies
Blockchain
Artificial Intelligence (AI)
Natural Language Processing (NLP)
Machine Learning (ML)
Big Data
Clinical Epidemiology
Biostatistics
Evidence-Based Medicine (EBM)
Longevity and Aging Studies
Medical Informatics
Expert Systems
Telemedicine
Human Genomics
Protection of Personal Data
ICO Regulation
Healthcare IT Regulation
Roadmap

EHF Personal Health (Personal Health Management Application)
Ethereum contract with ERC20 tokens
March 2018
Pre-ICO
March - April 2018
ICO, Round 1
June - July 2018
Start of software development
August 2018
Start of Core developers, AI, ML and health professionals hiring
August - December 2018
Launch of EHF Token Exchange Trades
December 2018
Database prototype
May 2019
Preliminary prototype for the screening module
July 2019
NLP test development, testing and implementation
October 2019
Alpha version of web and mobile (Android) applications (and initial closed testing)
December 2019
Alpha version with first paid services using EHF tokens
March 2020
Alpha version of IOS mobile application
March 2020
Alpha version of expert system for the primary diagnosis of the most common diseases and conditions on the basis of automated EBM-based algorithms (screening module and first wave of specialized diagnostics modules)
September 2020
Beta version of web and mobile applications, applying NLP, AI and ML technologies - public testing launch with basic diagnostic modules
March 2021
Marketplace prototype with EHF as main tokens
March 2021
Beta version with integration of major external data sources (available electronic medical records)
September 2021
Beta version with Marketplace alpha release
December 2021
Start of development graphene (EOS) - based blockchain solution for complete integration of all services in one ecosystem
December 2022
Beta version with Marketplace beta release
February 2023
Launch of graphene-based blockchain for project and conversion of ERC20 tokens to graphene based tokens
January 2024
Version 1.0
May 2024
Beta version of storage system for data in universal format for medical records and biomedical research aggregated data in graphene blockchain
September 2024
Version 2.0 and release version of storage system for data in universal format for medical records and biomedical research aggregated data in graphene blockchain
December 2025
EHF Biomed (Open IT platform for professionals)
Ethereum contract with ERC20 tokens
March 2018
Pre-ICO
March - April 2018
ICO, Round 1
June - July 2018
Start of software development
August 2018
Start of Core developers, AI, ML and health professionals hiring
August - December 2018
Launch of EHF Token Exchange Trades
December 2018
Database prototype
May 2019
NLP test development, testing and implementation
October 2019
Development of universal format for recording aggregated data from biomedical research (clinical guidelines, EBM summaries, systematic reviews, meta-analyses, clinical trials, observational studies)
March - December 2020
Alpha version, applying NLP technology
September 2020
DCFS (ETCD, Swarm, IPFS) integration
December 2020
Major data sources of medical data NLP processed and analyzed in database
May 2021
Beta version, applying NLP, AI and ML technologies, with first paid services using EHF tokens
September 2021
Beta version with API for data access for scientists
December 2021
Start of development graphene (EOS) - based blockchain solution for complete integration of all services in one ecosystem
December 2022
Launch of graphene-based blockchain for project and conversion of ERC20 tokens to graphene based tokens
January 2024
Version 1.0
May 2024
Alpha version of storage system for data in universal format for recording aggregated data from biomedical research in graphene blockchain
September 2024
Version 2.0 and beta version of storage system for data in universal format for biomedical research aggregated data in graphene blockchain
September 2025
View our news and Media
Visit our pages on Medium, Reddit, Twitter, groups on Facebook, LinkedIn, Slack and Telegram.
More to come very soon!
Token economy
100 000 000

EHF Tokens in total
Up to 2 000 000

EHF Tokens for sale on Private Placement (PP) and Pre-ICO
Up to 80 000 000

EHF Tokens for sale on ICO
Up to 25 000 000

EHF Tokens for sale on ICO, Round 1
259 000 ETH

Target on Crowdsale:
PP, Pre-ICO, ICO (Round 1)
8 000 ETH

Soft Cap
PP, Pre-ICO, ICO (Round 1)
ERC20

EHF Token type
ETH, BTC, EUR, USD

Purchase methods accepted:
PP
There will be no further production of EHF tokens after the ICO completion.
Tokens will be created with an ERC20 smart contract.
EHF Tokens will be distributed among Investors and the Team and will be available on the cryptoexchange markets.
Over time the tokens will reduce in number and could increase in price.



EHF-token holders could:

1
Get an investment income in case of EHF token price growth (crypto-exchange operations, direct purchase-sale)
2
Use them as payment options and additionally receive 10-50% discount for buying any Services developed under the EHF Project (Personal Health, Biomed) and by the Project Partners (applications, software modules / services, healthcare services, insurance plans, participation in clinical trials, observational studies and patient support programs etc.)
3
Use them to participate in special health campaign, programs and check-ups, to get access to special healthcare expert community
4
Use them to participate in the project development by voting (in proportion to the number of tokens)
5
Exchange them for other cryptocurrencies (BTC, BCC, ETH etc.) on various cryptocurrency exchanges and for fiat currency (USD, EUR, JPU, CNY etc.), in countries, where such operations are legal
6
Sell or buy them directly via compatible crypto wallets.
Meet our team
Nickolay Kryuchkov
Chief Executive Officer
Medical doctor (M.D., Stavropol State Medical Academy), Ph.D. (K.M.N., Immunology and Allergy, NRC Institute of Immunology FMBA Russia), Master of Public Health (M.P.H., Hebrew University of Jerusalem, Israel), Master of Business Administration (M.B.A., International Business School MIRBIS).
He has11 years of experience in pharmaceutical industry (as senior manager, head of department and C.E.O., 40+ completed projects of drug registration and clinical studies) and 20 years of experience in biomedical research, 6 junior researcher awards.
Nickolay is a founder and C.E.O. of R&D and service group of companies Clinical Excellence Group (registration of pharmaceuticals, food supplements, medical devices, clinical, non-clinical and observational studies, data analysis, strategic planning), operated in the Eurasian Economic Union and the European Union (from 2012).
He is an editor and co-author of Russia's first multimedia Course on Biostatistics, which was recommended by Organizational and methodological union of Russian High schools (Universities) on medical and pharmaceutical education for medical under- and postgraduates (2006), editor and co-author of Evidence-based Guideline for People living with HIV/AIDS, healthcare providers and public health professionals (2009).
He was a member of the Advisory Board of the Quality of Life (Health) project of the State Duma of the Federal Assembly of the Russian Federation (2010-2011), а member of the Advisory Board on the Reform and Modernization of the Healthcare System and Demographics Policy of the Civic Chamber of the Russian Federation (2012).
Nickolay is an author of 64 publications in Russian and International peer-reviewed journals and Conference Abstract Books, expert in healthcare for Russian media (TVC, 1TV, MIR, MIR 24, TV 360, OTR). His Biography is included in Marquis Who's Who in the World, 2012-2016 (29th-33rd editions) and 2000 Outstanding intellectuals of the 21st century, 2012-2015 (7th-10th editions).

LinkedIn See
Facebook See
CEG Group of Companies website See
CV (pdf) See
MIR TV: SR9009, innovative drugs (in Rus) See
MIR TV: Ineffective drugs on the market (in Rus) See
OTR: Homeopathic medicines vs. EBM (in Rus) See
TVC: Availability of drugs and pharmaceutical industry (in Rus) See
EBM Guideline on HIV / AIDS (2009, pdf, in Rus) See
Arnold Mitnitski
Advisor in Mathematical Modeling of complex biomedical systems, Systems Biology of the aging process, Advanced Data Analysis.
Ph.D., Research Professor of Medicine at the Dalhousie University, Halifax, Canada. He is a multidisciplinary scientist with research Interest in mathematical modeling of complex biomedical systems / systems biology of the aging process, and advanced data analysis.
Prof. Mitnitski is known for the development of the Frailty Index (FI, suggested together with Dr. K. Rockwood in 2001). The FI integrates a large amount of individual's health information (generally available in typical databases) in a single number and related to the biological age of the individuals. This FI is universally accepted as a valuable utility measure of health in individuals and populations which allows to stratify people by the risk of adverse outcomes (mortality, entering nursing home, time spending in hospital, etc.). It has numerous applications in a variety of areas, including epidemiology, clinical medicine, biology, and most recently even macro-economics. The FI has a strong theoretical foundation in a stochastic dynamic model of deficit accumulation based on the organism- environment interaction. Most recently, a new approach based on the complex dynamical network (being developed with the colleagues of the Department of Physics) allowed bringing the theoretical understanding of the origin of the FI to the next level.
Dr. Mitnitski published over 200 peer reviewed papers (most of them for the last 15 years), 136 are available in the PubMed, 23 papers were sited over 100 times; his (most conservative) Thomson Reuters h-index=40 (Google Scholar h-index=49). He is a member of the editorial boards/associate editor of the scientific journals: Biogerontology, BMC Geriatrics, Frontiers in Public Health, Journal of Aging Science, and a reviewer for the large number of journals, including Experimental Gerontology, Mechanisms of Ageing and Development, Journal of Gerontology, Age and Ageing, Demography. He is also a member of the College of Reviewers for the Canadian Institute of Health Research (CIHR). Being an elected Fellow of the Gerontological Society of America (GSA), he organized several symposia at the GSA annual meetings related to the Systems Biology of Aging and the Biological Age determination.

Personal website See
Twitter See
Facebook See
Research Gate See
Pesonal page on Dalhousie University website See
Biomedical Computation Review. Assembling the aging puzzle See
Article on the Canadian Institute of Health Research website See
Daria Khaltourina
Director, Public Health and Longevity Programs
Daria is a Board Member of the International Longevity Alliance and the Chair of the Board of the Russian Regional Russian NGO "Council for Public Health and Demography".
She received Ph.D. in anthropology, and after a few years of academic career she gradually moved into the area of public health advocacy, including anti-liquor and anti-tobacco control in Russia and internationally.
She currently works at promoting regulation beneficial for biomedical R&D, especially in the area of curing and preventing pathologies of aging. Daria is currently a coordinator of "Healthy Longevity" segment of the Russian National Technological Initiative.
She is the head of the Group of the Monitoring of Global and Regional Risks of the Russian Academy of Sciences, co-chairperson of the Russian Coalition for Alcohol Control, as well as the Russian Coalition for Tobacco Control. She is a laureate of the Russian Science Support Foundation Award in "The Best Economists of the Russian Academy of Sciences" nomination (2006).

International Longevity Alliance See
CV (pdf) See
Wikipedia See
Facebook See
Video: Legal problems of registering therapies to cure aging See
Video: EHA 2016 Brussels See
Nick Guldemond
Advisor in Health Policy and Management, Clinical Epidemiology, Public Policy, eHealth, Clinical Neurology, Clinical Diagnostics, Clinical Studies, Aging and Longevity Studies
Dr. Guldemond is Assoc. Prof. Integrated Care & Technology at the Institute Health Policy and Management, Erasmus University Rotterdam, the Netherlands.
He is policy advisor for the Health Ministry and consultant for various organisations: WHO, EU Programmes EIT KIC Health, KIC Digital, AAL, IMI and H2020. He is active numerous eHealth programmes: China, UK, Russian Federation, Italy, Norway, Poland, Germany, Belgium, Brazil, Iran, Finland, Romania and US. Often in collaboration with industry Pharma (Roche, Genzyme, J&J, Grunenthal), Medtech (Philips, MEDTRONIC, COCIR), Health IT (Microsoft, Ascom, Ortec, Vodafone) and finance (Rabobank, Natwest, RBS).
He was architect of the national eHealth and Big Data strategy. He is coordinator of EU EIP on Healthy and Active Ageing and member of the ISO Strategic Advisory Group on Ageing Societies.
Nick has a background in Electric Engineering, Medicine and Life Sciences. He was CEO & founder of the Medical Field Lab ie health innovation, for which he obtained prestigious research grants. He worked on innovation and medical curriculum development for different universities.

CV (pdf) See
LinkedIn See
Twitter See
Facebook See
Research Gate See
mHealth and Integrated Care (pdf) See
Healthcare: why a data-rich sector is still knowledge-poor See
Video: Internet of Things and Healthcare See
Aubrey De Grey
Advisor in Biomedical Gerontology, Aging and Longevity Studies, Biotechnology, Drug Assessment, Health Promotion
He is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world's highest-impact peer-reviewed journal focused on intervention in aging.
He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage.
Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations.
He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

SENS Research Foundation See
Twitter See
LinkedIn See
Facebook See
Wikipedia See
Research Gate See
Immortality Roadmap (pdf) See
A review of the biomedical innovations for healthy longevity See
The Guardian See
TED: A roadmap to end aging See
TED: Undoing aging See
Denis Rysev
C.T.O., Blockchain and Health Records
Denis is an IT professional, futurist and blockchain enthusiast from Moscow.
He works with blockchain technology from first month's after bitcoin announcement, for example he created first token for ICO in the field of reaching immortality for humans (IMC) and helped to make many successful ICOs like SONM, Golos, Kolionovo, Runeuro, NeuroDAO.
Denis has deep understanding of current and future technologies of humankind, especially in medicine related areas. He helped to develop Russian National Technological Initiative's roadmap for HealthNet branch. He also works in FinNet group (working on the future of finance and blockchain) and NeuroNet (using AI to understand human brain and to develop Human Machine Interfaces).
For 10 years he worked in the largest Russian Investment Holding "Finam" and developed several complex economical games, applying AI and Big Data technologies. The most popular game was a first one, accepting Bitcoins for the in-app and advertising payments in 2009. This game had educational focus and internal stock exchange. 500 000 registered users have been trained by the application. Moreover, this project passed through ICO even before Ethereum did.
Recently Denis works as a Team Lead on a project about radical change in the way, by which humans interact with computers, and a new way to implement AI and Machine Learning.
Areas of interest: Blockchain, Cryptocurrency markets, Smart contracts, Artificial Intelligence, Software Development, Mobile Application and Game Design.

LinkedIn See
Twitter See
Facebook See
GitHub See
Klout See
Golos See

Eray Ozkural
Director, Artificial Intelligence, Machine Learning and High-performance computing
Dr. Özkural has received his PhD in computer engineering from Bilkent University, Ankara. He has a deep and long-running interest in human-level AI. His name appears in the acknowledgements of Marvin Minsky's The Emotion Machine.
He has collaborated briefly with the founder of algorithmic information theory Ray Solomonoff, and in response to a challenge he posed, invented Heuristic Algorithmic Memory, which is a long-term memory system for general-purpose machine learning, solving one of the three grand AI challenges that Ray Solomonoff formulated. Some other researchers have been inspired by HAM and call the approach "Bayesian Program Learning". He has designed a next-generation parallel general-purpose machine learning platform.
He is the recipient of 2015 Kurzweil Best AGI Idea Award for his theoretical contributions to universal induction; he proposed physical arguments for the completeness of induction, and physical definitions of information closing the loopholes from the arbitrary choice of reference machine. He has previously invented an FPGA virtualization scheme for Global Supercomputing, Inc. which was internationally patented. He has also proposed an energy based currency, which can drive green energy proliferation.

Twitter See
LinkedIn See
CV See
GitHub See
Google Scholar See
DBLP See
Examachine.net Blog See
Medium See
Keith Comito
Senior Expert, Software Development
Keith is a mathematician, computer programmer and biotechnology enthusiast based in New York City. In addition to developing high-profile mobile applications such as HBO NOW and MLB At Bat, he explores the intersection of technology and biology at the Brooklyn community lab Genspace, and is a passionate supporter of research aimed at extending healthy human lifespan. Keith is also a practitioner of several martial arts, writer of music, and host of a retro video game–themed YouTube channel.
Seeing age-related disease as one of the most profound problems facing humanity, he now works to accelerate and democratize longevity research efforts through initiatives such as Lifespan.io.
He earned a B.S. in Mathematics, B.S. in Computer science, and M.S. in Applied Mathematics at Hofstra University, where his work included analysis of the LMNA protein.

LinkedIn See
Facebook See
Twitter See
Lifespan.io See
Lifespan's LinkedIn See
Lifespan's Youtube channel See
Life Extension Advocacy Foundation See
BAMTECH Media Company See
Video: Life Extension: How to Reach a Societal Turning Point See
ScIQ Video Interview: Challenges In American Innovation See
Forbes: Biological Games See
Engo Koc
Senior Expert in Investments, Entrepreneurship, Blockchain and Software Development
Serial Entrepreneur and Philantropist.
From an early age on, he was interested in business, stocks and trading and promptly started his first trading company in stocks shortly after reaching legal age. Following the financial crisis that soon ensued, he dropped out of university to focus fully on the company and has coached clients around the world on trading, as well as developed and sold trading algorithms to individuals and companies. After many years of successful business, he completed his certificate as DSI Investment Advisor and NIBE SVV Advisor on investments in stocks in 2014. Nowadays, he is a serial entrepreneur and dedicated philantropist, using his seven languages to connect and inspire people to embark on successful journeys.

LinkedIn See
Facebook See
Twitter See
De Stentor See (in Dutch)
Fabian Schütz
Senior Expert in Software Development, Natural Language Processing and Artificial Intelligence
Having setup an art space in the city of Munich at the age of 20 that for several years hosted a new exposition every weekend, he later went on to study computer science. Having been a developer, system and network engineer for 16 years, he mastered in 2017 with a focus on logic, cryptography and operating systems.
Since then, he has been working as a consultant and occasional free software developer with his own company, while also working as a photographer and filmmaker.

Facebook See
GitHub See
Personal website See
WelTraum26 See (in German)
Edwina Rogers
Advisor in Health and Social Security Policy, Longevity and Aging Studies, Primary Care, Government Affairs and Lobbying, Strategic Planning and Entrepreneurship, Media and Public Relations, Legal and Regulatory Affairs
Edwina Rogers has served in public policy positions in the US Senate, White House, private and international sectors for over twenty years. Edwina is currently the C.E.O. of The Global Healthspan Policy Institute (GHPI). GHPI is a Washington-based think tank and international coalition dedicated to extending the time period that humans are healthy through measuring and managing aging and age-related diseases.
Previously she served as the Executive Director at the Secular Coalition for America (SCA), a non-profit coalition that represents the diverse and growing voice for separation of religion and government. She served as the founding Executive Director of the Patient-Centered Primary Care Collaborative from 2006-2011, a Washington DC trade association, responsible for the national Patient-Centered Medical Home movement and implementing the model around the US. Edwina served as Vice President, Health Policy for The ERISA Industry Committee (ERIC) in Washington, DC from May 2004 until January 2009. ERIC advocates the employee benefits and compensation interests of America's major employers.
Edwina has been a public policy expert for over twenty years and has worked for two Presidents and four Senators. She was an Economic Advisor for President George W. Bush at the White House during 2001 and 2002 at the National Economic Council, focusing on health and social security policy. Ms. Rogers was General Counsel of the National Republican Senatorial Committee during the Republican take-over of the Senate in 1994. She worked for Senator Lott while he was Majority Leader in 1999 and she handled health policy for Senator Sessions in 2003 and 2004. Edwina worked on International Trade matters for President Bush at the Department of Commerce from 1989 until 1991. She received her BS in Corporate Finance from the University of Alabama and a JD from Catholic University in Washington DC. Ms. Rogers was a Fellow at the Kennedy School at Harvard during 1996.
She served on the Board of Directors of Semco Energy, Inc. (NYSE: SEN) a natural gas distribution company.
Edwina has been a regular contributor of conservative newspaper columns, health and policy journals and a regular strategist on cable news television.

Wikipedia See
LinkedIn See
Twitter See
Facebook See
Instagram See
Global Healthspan Policy Institute See
Sviatoslav Plavinski
Advisor in Clinical Epidemiology, Biostatistics, Advanced Data Analysis, Diagnostic Algorithms, Machine Learning in Medicine, Legal and Regulatory Affairs
Sviatoslav is a biostatistician, public health specialist, and educator, specializing in Biostatistics, Mathematical Modelling and Lifestyle Risk Factors Assessment including those for infectious (HIV/AIDS) and non-communicable diseases.
Dr. Plavinski completed study at the First Medical Institute named after Pavlov there (Medical Doctor degree). He has received training at Erfurt Medical Academy (Germany) before moving to full-time research position at the Institute for Experimental Medicine where he earned his Ph.D. degree. Main focus of his interest in 1990s was cardiovascular diseases and reasons for rapid increase in mortality in Russia in 1990s. In 1998 he joined Medical Academy for Postgraduate Studies where he earned D.Sc. degree and became Dean of the College of Public Health and participated in numerous international projects. Focus of his interests moved to risk factors of infectious diseases, first of all HIV/AIDS and STI, with accent on statistical aspects of risk studies.
He was an expert for the Russian delegation at G8 summit in 2006 and 2014, Baltic Sea Communicable Disease Task Force, St. Petersburg city commission on health care quality. He did expert work for WHO and UNDP. Dr. Plavinski is a Board member of the Open Health Institute – largest Russian non-profit organization leading preventive efforts against HIV/AIDS among vulnerable population.
Dr. Plavinski's research interests include modelling infectious diseases spread, quality improvement in area of preventive work and evidence-based assessment of prevention effectiveness and cost-effectiveness. He is very much interested in health law, especially public health laws and its influence on risk behaviour.
He is an author and co-author of more than 250 research publications, including several monographs. Dr. Plavinski reviewed articles for J. Epidemiol., Social and Behavioral Medicine, BMJ, Social Science in Medicine and is a member of editorial board of several Russian medical journals.
He actively worked in the field of Clinical Trials and Health Technologies Assessment, as biostatistician and modeller. He is long-term user and author of several books on such statistical systems as SAS and R.
Sviatoslav is an author and co-author of 270 research articles, chapters and monographs, including articles in British Medical Journal (2003, 2005) and monographs 'Biostatistics. Analysis of Biomedical Data with SAS System' (2005), "Introduction to Biostatistics for Medicine"(2011), "Variants of drug provisions for Russia. Lessons from Europe and other countries" (with V. Vlassov, 2013) [in Russian].
He is an Editorial board member: Russian Family Physician Journal, Herald of the North-West State University, HIV-infection and Immunosuppression.
Prof. Plavinski reviewed articles for: J Epidemiol., Social and Behavioral Medicine, Social Science in Medicine, BMJ. He is a statistical reviewer for Psychopharmacology and Biological Narcology Journal.
Dr. Plavinski is currently Chief Academic Officer at the North-West State Medical University, Saint-Petersburg, and Chair of the Department of Teaching, Philosophy and Law there. He also teaches courses for Master of Public Health students and fellowship students of other specialities as well as physicians.

CV See
Research Gate See
Video: Modern Meta-analysis (in Rus) See
Video: Introduction to EBM (in Rus) See
João Pedro de Magalhães
Advisor in Aging and Longevity Studies, Genetics and Genomics, Therapy and Prevention of Ameliorate Age-Related diseases, Technological Trends, Transhumanism
João Pedro graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and in 2004 obtained a PhD in Biological Sciences from the University of Namur in Belgium. Following further training in computational biology and genetics at Harvard Medical School (Boston, USA), in 2008 Dr. de Magalhaes joined the University of Liverpool in the UK as a faculty member to develop his own group on genomic approaches to ageing.
His research on genetics, ageing and longevity has widely been featured in scientific magazines (Science, Nature, Scientific American, New Scientist, etc.).
In addition, he has a long-term interest in technological trends and their future impact on society. His work on predicting how technology will shape the human condition has been published in magazines such as Futures and The Futurist, and in newspapers like The Independent.
Dr de Magalhaes has given over 100 invited talks, including a TEDx talk, and makes regular media appearances (BBC, CNN, the Washington Post, the Financial Times and many others). He is also an advisor/consultant for various organizations, including nonprofit foundations and biotech companies.

Independent Genetics of Aging Group See
Personal website See
Twitter See
Facebook See
LinkedIn See
Google Scholar See
Research Gate See
Bioinformatics: Meta-analysis of age-related gene expression See
TED: Showing down ageing See
Kalluri Subba Rao
Advisor in Clinical Genetics, Aging and Longevity Studies, Biochemistry, Neurobiology, Biotechnology
Professor, Ph.D., D.Sc. (IISc), FAS-AP, FAMS, FNASc, FNA.
He is an Indian National Science Academy Honorary Scientist, working at the School of Medical Sciences, University of Hyderabad, India.
He has worked as a Professor of Biochemistry / Neurobiology at the University of Hyderabad, and as an INSA-Senior Scientist / Honorary Scientist & Professor at the Centers for Biotechnology and Innovative Research, Institute of Science and Technology, Jawaharlal Nehru Technological University, Kukatpally, Hyderabad.
His research interests include Biochemistry and Molecular Biology of the developing and aging brain with special reference to DNA-damage and its repair. He has more than 120 research publications in national and international journals and books. His contributions include establishing the link between aging and decreased DNA repair, particularly the base excision repair, in the brain.
He is presently working on a monograph containing the latest scientific information about the process of aging in higher organisms and also examining the available related traditional Indian (Vedic) concepts. He has advocated for the establishment of Institutes or Centers for multidisciplinary scientific study of the phenomenon of aging and the associated diseases in India.

CV See
Research Gate See
Academia See
Semantic Scholar See
Should India Promote Scientific Research on Aging? See
Video: Healthy Ageing in the Changing World 2013 See
Victor Solntsev
Advisor in Financial Management, Business Models, Coaching, Project Management, Risk Assessment, Investment Strategy, Business Development
Victor is the Founding partner and CEO of consultancy company (est. 2003) working in the field of investment projects evaluation and strategy development. He also presents his practical-oriented trainings for top-managers, corporate specialists and governmental officials, also teaches at leading business schools of Russia and Kazakhstan, accredited by AMBA, as an invited professor. He is a full member of geopolitics and national security branch of Russian academy of natural sciences (RAEN).
Victor is a member of National association of independent directors. He is a member of the Commission for consultancy and financial audit at the All-Russian Public Organization "Opora Rossii", largest association of Russian SME.
He received Ph.D. in Robotics, AI and Control Systems at the Bauman University and passed through training programs at IESE Business School (Spain), Kingston BS (Great Britain), Schulich School of Business (Canada) for top-management education.
He currently works at Bauman University at the professional development department of Institute for Modern Educational Technologies. He is an expert in assessment and training professional competencies, especially in the area of corporate governance, corporate strategy, managing innovation and investment projects. He fulfilled a variety of scientific research and consultancy projects for governmental bodies, corporations and companies. Now he is a mentor of several innovation technology start-ups.

Personal website (in Rus) See
Facebook See
LinkedIn See
Paul Spiegel
Attorney at Law, Advisor in Legal and Regulatory Affairs (in the U.S.A.) for the biotechnology and IT industry, business structuring and startups, international business consulting, domestic and international intellectual property practice, publishing, licensing and event production
Paul Spiegel graduated cum laude from the University of California, Berkeley in 1979 and from Boalt Hall School of Law in 1983 (Juris Doctor). He has attended Harvard Law School, the University of Paris, Sorbonne, and International Christian University in Tokyo. Trained in international business law, he worked on Wall Street, on Montgomery Street and in Tokyo before entering private practice in IP, business and entertainment law in San Francisco.
Long an advocate of progressive ideas and causes, he has focused on the biology of aging and regenerative medicine since learning about the work of Dr. Aubrey de Grey in 2005 through a long friendship with John Furber of Legendary Pharmaceuticals. Mr. Spiegel currently advises clients in biotechnology and longevity science, and is researching legal issues relating to a greatly-extended human lifespan.
Mr. Spiegel sits on the Board of Directors of the International Longevity Alliance and the American Longevity Alliance and is an advisor to the Lifeboat Foundation. An ardent transhumanist, he is a member of Humanity+ and carboncopies.org and is also researching social, legal and operational issues relating to the possibility of substrate-independent minds and a potentially immortal humanity.

CV (pdf) See
LinkedIn See
Facebook See
International Longevity Alliance See
Life Extension Advocavy Foundation See
Lifeboat Foundation See
California Life Sciences Association See
Artemy Malkov
Advisor in Strategic Planning and Entrepreneurship, Software Development, Artificial Intelligence, Machine Learning and Natural Language Processing.
Artemy is a scientist and entrepreneur, AI and Machine Learning expert.
In 2006 he bootstrapped a Flexis company which performed a 2-3x yearly growth 5 years in a row, including global expansion. In 2010, Artemy started a BI product company and raised $6M of venture funding. The company became an industry leader and was later acquired by a nationwide system integrator. In 2015, Artemy established a new brand Data Monsters, a Palo Alto based R&D lab and consulting company which is focused on real-time intelligent big data. The company develops advanced algorithms to solve fundamental problems in NLP, Deep learning, and predictive analytics. Data Monsters is involved in the community by supporting events, working with universities, and partnering with vendors like NVIDIA, Google, IBM, Intel, Amazon, and Cray.
Artemy is a frequent speaker at AI events. He is evangelizing the ideas of smart feature engineering methods to fight the problem of the long tail distributions in machine learning. He is one of the influencers in the area of product management and marketing and the author of the "Genetic theory of product design".

Facebook See
LinkedIn See
Oliver Medvedik
Senior Expert, Human Genetics, Genomics and Biochemistry
Oliver Medvedik is a co-founder of Genspace citizen science laboratory in Brooklyn NY, earned his Ph.D. at Harvard Medical School in the Biomedical and Biological Sciences program.
As part of his doctoral work he has used single-celled budding yeast as a model system to map the genetic pathways that underlie the processes of aging in more complex organisms, such as humans.
He has worked as a biotechnology consultant, taught molecular biology to numerous undergraduates at Harvard University and mentored two of Harvard's teams for the international genetically engineered machines competition (IGEM) held annually at M.I.T.
Areas of interest: Biomedical Engineering, Aging and Longevity Studies, Molecular and Cellular Biology, Genetics, Biochemistry, Life Extension Advocacy.

LinkedIn See
Genspace See
Lifespan.io See
Lifespan's LinkedIn See
Terreform See
The Kanbar Center for Biomedical Engineering See
Lyle Dennis
Senior Expert in Clinical Medicine and Biomedical Studies
Dr. Dennis is Assistant Clinical Professor of Neurology at Columbia University in New York. He is also Chief of Neurology at Good Samaritan Regional Medical Center in New York.
He received his M.D. from Albert Einstein Colleges of Medicine and completed his residency in Neurology at Columbia University, with a fellowship in Neurocritical Care.
He has been involved full time in the clinical practice of neurology for the past 20 years caring for many thousands of patients with neurological disease. He also established stroke centers in several area hospitals in the New York/New Jersey region.
In addition to his work as a neurologist Dr. Dennis is deeply interested in the use of technology to expand health human lifespan. He is particularly focused on the use of artificial intelligence and blockchain in healthcare.
He has been a serial entrepreneur and early investor in Augmedix and iBeat, and holds the role of Chief Medical Officer for Health Monitor Network where he has conceived and developed groundbreaking health tracking apps.

CV See
Linkedin See
Facebook See
Twitter See
Mihai Manolache
Director, Observational Studies and Patient Support Programs
Mihai holds a Ph.D. in Biostatistics from "Carol Davila" University of Medicine and Pharmacy of Bucharest; a Master Degree in Biostatistics from the University of Bucharest. Mihai has completed a post-graduate course in Immunology and Genetics from HMX - Harvard Medical School. He has graduated the Law School in Bucharest, having a specialization in medical research laws and regulations. Mihai has also graduated the Economics Faculty with a specialization in Administrative Sciences.
Mihai Manolache is the founder of CEBIS International, a global contract research organization headquartered in Lugano, Switzerland which helps biopharmaceutical and medical devices companies to perform the clinical investigations for their products before reaching the market.
Mihai has expertise in planning, managing and coordinating more than 200 international clinical studies in: Romania, Bulgaria, Croatia, Hungary, Serbia & Montenegro, Macedonia, Moldova, Greece, Turkey, India, Spain, Switzerland, Italy, Germany, Ukraine, Estonia, Latvia, Lithuania. Mihai has expertise in the following therapeutic areas: Cardiology, Oncology, Diabetes, CNS, Hematology, Urology, Gastroenterology, Pediatrics, HIV, Immunology, ObGyn, Respiratory, Dermatology.

LinkedIn See
CEBIS Company website See
Zamir Akimov
Advisor in Blockchain, Crypto Economics, Legal and Regulatory Affairs
Zamir is a Vice-President of Russian Association of Cryptocurrency and Blockchain. Also he is a founder and CEO at NeuroDAO Crypto Fund.

Facebook See
Twitter See
Artyom Gil
Senior Epidemiologist and Biostatistician
Public Health Researcher, Epidemiologist.
Artyom is a Member of the International Longevity Alliance and of the Russian Regional NGO "Council for Public Health and Demography".
He received M.D. degree in Internal Medicine, M.P.H and Ph.D. degrees in Public Health. He continues his academic work in Higher School of Health Administration in Moscow Medical University, doing research on determinants of premature mortality in Russia, including alcohol, tobacco, economic and health policy aspects.
Artyom is the current expert of the WHO collaborating centre, co-facilitates trainings for data collectors, and organizes country level population based surveys of risk factors of non-communicable diseases in countries of Eastern Europe and Central Asia.
Being a member of the Public Council of the Federal Service on Regulation of Alcohol Market (Russia), he provides expertise in the area of alcohol control. He is also involved in public health advocacy in the field of tobacco control in Russia and internationally.
Artyom is an author of collective monograph "Prevention of Ageing for All", he utilizes epidemiology for synthesis of evidences of effective interventions targeting ageing.

Research Gate See
Google Scholar See
I.M. Sechenov Moscow State Medical University See
Sergey Baryshev
Senior Software Developer, Web and Mobile Applications Development, IT Infrastructure
Sergey created software for accounting and planning of enterprise resources, optimization of production management (Garment factory "Trikotazhnitsa", Russia, Kineshma city) and logistics (Corrugated board production PJSC "Gofron", Russia, Kashira city).
He has 13-year experience in the development of websites (more than 40 completed projects), mobile applications, expert and recommendatory systems (including "Litres Innovation" – HighLoad website and Mobile App, resident of Skolkovo, Moscow).
For more than 4 years he worked as Head of the Department of IT technologies in a large company, located in Moscow.
Sergey is a founder and C.E.O. of the Russian Business Directory (sitebase), the Industrial Directory of Pumps (ProPumps).
He graduated as Master of Economics ("Production Management") in the Russian State Agrarian University - Moscow Timiryazev Agricultural Academy.
Technical Skills:
Delphi/Pascal, C#, PHP, Node.js, Perl (MVC, Fast-CGI, Async), Python, Java; NGINX/APACHE, Mysql, MS SQL, Mongodb, PostgreSQL, Memcached; Virtualization: VMware, Xen, chroot;
Gettext, JS, XSLT/XML, XSL, TurboXSLT; HTML5, CSS, Pug/Jade, Javascript, jQuery, JSON API, OAuth, Geo API, integration with payment systems, SVN, GIT, JIRA; CAD program Comtense (from CAD Nuvocut);
Experience in Anti DDoS, CSP (content security policy);
Load Balancing, Highload, BigData, Cloud computing.
Areas of interest: Software Development, Big Data, Data Protection and Security, Moblile Applications, SaaS, Clinical Trials Management Systems.

LinkedIn See
Facebook See
Join the Private Placement
December 1, 2017 - April 9, 2018
Private Placement is the most beneficial stage of ICO for an EHF investor and provides maximal bonus ever (50-70% discount to the ICO, Round 1, price) depends on:
the investment size (minimal one is 2 ETH or 0.2 BTC, or 2500 USD, or 2000 EUR);
day of purchase of EHF tokens (the sooner the more profitable).
The current BTC - ETH, USD - ETH, EUR - ETH exchange rates are applying in case of investments in BTC, USD or EUR.
Please note, the smart contract isn't active for this stage and all the transactions are handled manually
Discounts to the ICO, Round 1, first day price (0.01 ETH) by month and amount of transaction:
10 ETH or more
30 ETH or more
60 ETH or more
120 ETH or more
December 2017
60%
65%
70%
70%
January 2018
55%
60%
65%
70%
2 ETH or more
10 ETH or more
30 ETH or more
120 ETH or more
February 2018
50%
55%
60%
70%
March 2018
45%
50%
55%
70%
Buy EHF tokens using ETH
Starting from
2.0 ETH
1. Click the orange button below.
2. Fill in the form: your email; your Ethereum account A address, using for the payment in ETH; your Ethereum account B address to get EHF tokens; investment size (in ETH) - minimal amount is 2 ETH; your comments.
NB! Your Ethereum accounts A and B may be the same. At the Private Placement Stage you may invest any amount starting with 2 ETH. More the investment size more the Bonus.
3. Submit the form by clicking the button at the bottom of the form and see the EHF Etherium account address.
4. Make the transaction from the Ethereum account A to the EHF Ethereum account, using your Wallet.
NB! Please carefully check all entered information before confirming the transaction.
5. In 3 days after that check your email for the confirmation of transaction and number of tokens reserved.
6. Get all the purchased EHF tokens during the Pre-ICO stage.
NB! All the EHF tokens purchased at this stage will be sent to the Ethereum account B address.

Thank you!
Invest now
Buy EHF tokens using BTC
Starting from
0.2 BTC
1. Click the orange button below.
2. Fill in the form: your email; your Bitcoin account A address, using for the payment in BTC; your Ethereum account B address to get EHF tokens; investment size (in BTC) - minimal amount is 0.2 BTC; your comments.
NB! Your accounts A and B must not be the same. At the Private Placement Stage you may invest any amount starting with 0.2 BTC. More the investment size more the Bonus.
3. Submit the form by clicking the button at the bottom of the form and see the EHF Bitcoin account address.
4. Make the transaction from the Bitcoin account A to the EHF Bitcoin account, using your Wallet.
NB! Please carefully check all entered information before confirming the transaction.
5. In 3 days after that check your email for the confirmation of transaction and number of tokens reserved.
6. Get all the purchased EHF tokens during the Pre-ICO stage.
NB! All the EHF tokens purchased at this stage will be sent to the Ethereum account B address.

Thank you!
Invest now
Buy EHF tokens using USD / EUR
Starting from
2500 USD / 2000 EUR
1. Click the orange button below.
2. Fill in the form: your email; your phone number; your Ethereum account B address to get EHF tokens; investment size (in USD or EUR) - minimal amount is 2500 USD / 2000 EUR; your comments.
NB! At the Private Placement Stage you may invest any amount starting with 2500 USD / 2000 EUR. More the investment size more the Bonus. Please carefully check all entered information before submission.
3. Submit the form by clicking the button at the bottom of the form and wait fot the answer via email.
4. In 3 days after that check your email for the letter from the EHF Team.
5. Make the transaction and wait for
the confirmation and number of tokens reserved.
6. Get all the purchased EHF tokens during the Pre-ICO stage.
NB! All the EHF tokens purchased at this stage will be sent to the Ethereum account B address.

Thank you!
Invest now
China:
Currently, Chinese citizens can't participate in any ICOs, in accordance with the Statement of People's Bank of China
We will inform our Partners / Investors about the progress with this issue.
See the Statement (in Chinese)

The United States of America:
The U.S. citizens and residents could participate in ICOs, but there are novel regulation rules for that.
Participation of U.S. citizens and residents in eHealth First's ICO is not prohibited by the Securities and Exchange Commission ("SEC") or U.S. law. However, despite the recent investigation of The DAO and SEC Report No. 81207 ("SEC Report"), establishing the status of an Initial Coin Offering ("ICO") as "securities" subject to regulation under U.S. law, ICO investors are uncertain, especially with respect to ICO's offered by foreign companies, such as eHealth First.
Basing on the review of the U.S. current legislation, the eHealth First Project Team considers, that the EHF Token isn't a security.
Nevertheless, eHealth First makes no promise of compliance with SEC regulations with regards to this ICO. Although eHealth First fully believes in the innovation and success of this project, it advises all potential investors that ICO investments carry certain risks and uncertainties. U.S. citizens and residents seeking to invest in this ICO are urged to independently assess all emerging risks. We provide the Guide for U.S. investors to help foster understanding of the current legal status of ICOs in the U.S., specifically ICOs offered by foreign companies, but we are not providing legal advice on this subject.
See the ICO Legal Guide for U.S. investors (in English)

ICO, Round 1

July - September, 2018 (TBD)
up to 25 000 000
Number of tokens
NO DAILY LIMIT!
0.01 ETH
Price at launch
+0.25%
Daily price increment
Private Placement will be completed within
Days
Hours
Minutes
Seconds
Leave your email below to receive updates
By clicking on the button, you consent to the processing of personal data and agree with the privacy policy, in accordance with your local legislation
Buy EHF tokens: investor@ehfirst.io
Special conditions for investors at the Private Placement and Pre-ICO stages

Join the Project Team: nkryuchkov@ehfirst.io

Media: media@ehfirst.io

Join the Bounty Program: bounty@ehfirst.io

Ask a question or make an offer: support@ehfirst.io

Copyright © 2017-2018 eHealth First Project. All rights reserved.
Privacy Policy